108.20
+1.69%
Close of 9 Nov 2026, in CHF
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medacta Group
Its shares trade on SIX under the ticker MOVE.SW. It has been listed since 4 April 2019. In the fiscal year to 31 December 2025, it reported revenue of €688.3m and net income of €96.1m. At that date it held total assets of €916.9m and shareholders' equity of €456.2m.
Medacta Group SA engages in the development, manufacture, and distribution of orthopedic and neurosurgical medical devices. The company is headquartered in Castel San Pietro, Ticino. The company went IPO on 2019-04-04. The firm develops, manufactures and distributes orthopaedic and neurosurgical medical devices. The firm designs a number of products, such as hip products, including hip replacement, hip anatomy, hip diseases, and other products for the preparation of hip surgery; knee product, which encompasses knee anatomy, knee diseases, knee replacement, the stability of the knee and for the preparation of knee surgery; shoulder product, which includes shoulder anatomy, shoulder disease, shoulder replacement, and for the preparation of shoulder operation, and spine product, which includes products for spinal treatments, spinal anatomy and for surgery, among others. Additionally, the Company also offers training and support to healthcare professionals.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 4 Apr 2019
- Employees
- 1,101
Leadership
Pay as last reported
- Mr. Alberto SiccardiNon-Executive Chairman of the BoardCHF 325,638
- Mr. Francesco SiccardiChief Executive Officer, Member of the Group Executive ManagementCHF 1.9m
- Mr. Corrado FarsettaChief Financial Officer, Member of the Group Executive Management
- Mr. Alessandro SiccardiSupply Chain Director, Member of the Group Executive Management
- Mr. Victor BalliNon-Executive Lead Independent DirectorCHF 214,599
- Mrs. Maria Siccardi TonolliNon-Executive DirectorCHF 127,795
- Mr. Riccardo BragliaNon-Executive Independent DirectorCHF 119,519
- Mr. Philippe WeberNon-Executive Independent DirectorCHF 141,250
- Mr. Strada ReginaIR Contact Officer, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 99
- Social
- 99
- Governance
- 45
- Direct emissions (scope 1)
- 1,296 t
- Energy emissions (scope 2)
- 620 t
- Women in the workforce
- 32%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medacta Group SA has several strengths that contribute to its success in the market. Firstly, the company possesses a strong reputation for its innovative medical devices and solutions. This reputation has been built through years of research and development, leading to high-quality products. Additionally, Medacta Group SA has established strong relationships with healthcare professionals and institutions globally, which allows for widespread distribution and adoption of its products.
Weaknesses
- Despite its strengths, Medacta Group SA also faces certain weaknesses that need to be addressed. One major weakness is the company's limited geographic presence compared to some of its competitors. Medacta Group SA primarily operates in Europe and Asia, which limits its market reach and potential for growth in other regions. Another weakness is the company's heavy reliance on a few key products for its revenue. This lack of diversification exposes Medacta Group SA to potential market volatility and competitive threats in the long term.
Opportunities
- There are several opportunities that Medacta Group SA can capitalize on to further enhance its market position. Firstly, the growing global demand for minimally invasive surgical procedures presents a significant opportunity for Medacta Group SA's innovative medical devices. By continuing to invest in research and development, the company can develop new products that cater to this trend and gain a competitive edge. Additionally, expanding into untapped markets such as North America and Latin America can help Medacta Group SA diversify its revenue streams and reduce its dependence on specific regions.
Threats
- Despite the opportunities, Medacta Group SA faces several threats that may hinder its growth and profitability. One major threat is intense competition in the medical device industry. Competitors with larger market shares and broader product portfolios pose a challenge to Medacta Group SA's market position. Additionally, stringent regulatory requirements and the need for rigorous clinical trials can increase the time and cost of bringing new products to market, potentially impacting Medacta Group SA's ability to stay ahead of the competition. Lastly, economic downturns and healthcare budget constraints in key markets can reduce the demand for medical devices, affecting Medacta Group SA's sales and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.